Clinical Trials Browser

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03761056 2024-12-04

ZUMA-12

Phase 2 Completed

42 enrolled 20 charts

Lymphoid

Lymphoma, B-Cell

NCT02406092 2024-11-21

Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A

Phase 3 Completed

139 enrolled 14 charts

Lymphoid

Lymphoma, Non-Hodgkin

NCT02400281 2024-07-03

Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients

Phase 1/2 Completed

28 enrolled 15 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02926833 2024-03-06

ZUMA-6

Phase 1/2 Completed

37 enrolled 28 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02626338 2023-12-20

Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML

Phase 1/2 Completed

16 enrolled 12 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04196491 2023-08-23

KarMMa-4

Phase 1 Completed

13 enrolled

Plasma cell

Multiple Myeloma

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Phase 1 Completed

37 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT02992743 2023-04-11

Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma

Phase 2 Completed

23 enrolled 25 charts

Sarcoma

Neoplasms, Liposarcoma, Myxoid

Clinical Trials

ZUMA-2

ALPHA

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

ZUMA-5

FT576 in Subjects With Multiple Myeloma

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

ZUMA-7

ZUMA-2

A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

ACTolog

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

ZUMA-12

Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A

Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients

ZUMA-6

Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML

KarMMa-4

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma

TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL

Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

NY-ESO-1

Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML)

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia

Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)

A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)

A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia

A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia

CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy

Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients

ECO-1

A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)

Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

BIFROST

Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.

Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia